253 related articles for article (PubMed ID: 14584065)
1. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
Solit DB; Morris M; Slovin S; Curley T; Schwartz L; Larson S; Kattan MW; Hartley-Asp B; Scher HI; Kelly WK
Cancer; 2003 Nov; 98(9):1842-8. PubMed ID: 14584065
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
Kelly WK; Zhu AX; Scher H; Curley T; Fallon M; Slovin S; Schwartz L; Larson S; Tong W; Hartley-Asp B; Pellizzoni C; Rocchetti M
Clin Cancer Res; 2003 Jun; 9(6):2098-107. PubMed ID: 12796374
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
Hudes GR; Nathan FE; Khater C; Greenberg R; Gomella L; Stern C; McAleer C
Semin Oncol; 1995 Oct; 22(5 Suppl 12):41-5. PubMed ID: 7481860
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
[TBL] [Abstract][Full Text] [Related]
6. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
7. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Pienta KJ; Smith DC
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
[TBL] [Abstract][Full Text] [Related]
9. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
[TBL] [Abstract][Full Text] [Related]
10. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
Galsky MD; Small EJ; Oh WK; Chen I; Smith DC; Colevas AD; Martone L; Curley T; Delacruz A; Scher HI; Kelly WK
J Clin Oncol; 2005 Mar; 23(7):1439-46. PubMed ID: 15735119
[TBL] [Abstract][Full Text] [Related]
11. Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.
Vaughn DJ; Brown AW; Harker WG; Huh S; Miller L; Rinaldi D; Kabbinavar F
Cancer; 2004 Feb; 100(4):746-50. PubMed ID: 14770430
[TBL] [Abstract][Full Text] [Related]
12. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
13. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Amato RJ; Hernandez-McClain J; Henary H
Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
Hudes GR; Obasaju C; Chapman A; Gallo J; McAleer C; Greenberg R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):6-11. PubMed ID: 7597435
[TBL] [Abstract][Full Text] [Related]
15. Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination.
Athanasiadis A; Tsavdaridis D; Rigatos SK; Athanasiadis I; Pergantas N; Stathopoulos GP
Anticancer Res; 2003; 23(3C):3085-8. PubMed ID: 12926166
[TBL] [Abstract][Full Text] [Related]
16. Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer.
Kitamura T; Suzuki M; Nishimatsu H; Kurosaki T; Enomoto Y; Fukuhara H; Kume H; Takeuchi T; Miao L; Jiangang H; Xiaoqiang L
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S34-40. PubMed ID: 20094950
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
[TBL] [Abstract][Full Text] [Related]
18. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
[TBL] [Abstract][Full Text] [Related]
19. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.
Kikuno N; Urakami S; Nakamura S; Hiraoka T; Hyuga T; Arichi N; Wake K; Sumura M; Yoneda T; Kishi H; Shigeno K; Shiina H; Igawa M
Eur Urol; 2007 May; 51(5):1252-8. PubMed ID: 17208356
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer.
Berry W; Friedland D; Fleagle J; Jackson D; Ilegbodu D; Boehm KA; Asmar L
Clin Genitourin Cancer; 2006 Sep; 5(2):131-7. PubMed ID: 17026801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
